Blog

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced...

It is with heavy hearts we share that our beloved NETCONNECT Mentor and dear friend of LACNETS, Kelli Devan Edwards, passed away on...

LACNETS hosted over 100 NET patients and caregivers in Santa Monica on Nov 11th to celebrate NET Cancer Day. Everyone appreciated having...

On Oct 22, 2023, Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®)...

In "Against the Tide: The Mary Donlevy Story," Mary shares her NET journey as part of the 'Stories of Hope' video series, a joint effort...

Receiving scan or test results can be one of the most anxiety-inducing experiences anyone touched by cancer can experience. You know...

Many NET patients are on a somatostatin analog (SSA), also known as “the shot” in the patient community. The purpose of the shot is to...

First, let’s review some basic concepts… Theranostics is an approach that combines diagnosis and treatment by targeting the same...

The Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS) and Carcinoid Cancer Foundation (CCF) are excited to announce a...

An Overview of PRRT Peptide Receptor Radionuclide Therapy Original post April 2, 2019; Updated 12/17/2022 By now, you’ve probably heard...